The burgeoning popularity of semaglutide , initially for metabolic conditions, is creating significant interest within the UK , prompting a notable shift in hormone trends. Access these treatments remains a complex challenge , with public healthcare system coverage currently limited and specialist practices offering treatment at a higher cost . Wor